Compare BLLN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | TMDX |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | N/A | 2019 |
| Metric | BLLN | TMDX |
|---|---|---|
| Price | $80.12 | $113.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $126.71 | ★ $148.22 |
| AVG Volume (30 Days) | 281.7K | ★ 934.6K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $45.96 | $24.51 |
| Revenue Next Year | $30.11 | $18.72 |
| P/E Ratio | ★ N/A | $22.43 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $61.96 | $81.92 |
| 52 Week High | $138.70 | $156.00 |
| Indicator | BLLN | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 48.57 |
| Support Level | $80.39 | $109.43 |
| Resistance Level | $83.20 | $131.86 |
| Average True Range (ATR) | 6.77 | 5.39 |
| MACD | 1.35 | 1.73 |
| Stochastic Oscillator | 49.68 | 78.08 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.